Karyopharm Therapeutics (NASDAQ:KPTI) will post its quarterly earnings results before the market opens on Thursday, March 15th. Analysts expect Karyopharm Therapeutics to post earnings of ($0.65) per share for the quarter.
Karyopharm Therapeutics (NASDAQ KPTI) opened at $17.01 on Wednesday. The firm has a market capitalization of $821.11, a PE ratio of -6.39 and a beta of 3.62. Karyopharm Therapeutics has a fifty-two week low of $7.48 and a fifty-two week high of $18.00.
In other Karyopharm Therapeutics news, EVP Christopher Brett Primiano sold 2,500 shares of the stock in a transaction that occurred on Monday, March 5th. The stock was sold at an average price of $16.03, for a total transaction of $40,075.00. Following the completion of the transaction, the executive vice president now owns 4,881 shares of the company’s stock, valued at $78,242.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael Kauffman sold 10,000 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $9.16, for a total value of $91,600.00. Following the transaction, the chief executive officer now directly owns 522,143 shares of the company’s stock, valued at approximately $4,782,829.88. The disclosure for this sale can be found here. Insiders have sold 66,500 shares of company stock valued at $824,800 in the last three months. Insiders own 14.71% of the company’s stock.
A number of equities analysts recently weighed in on the company. Canaccord Genuity upped their price target on Karyopharm Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Monday. BidaskClub raised Karyopharm Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 8th. Royal Bank of Canada reissued a “buy” rating and set a $22.00 target price on shares of Karyopharm Therapeutics in a report on Friday, March 2nd. ValuEngine raised Karyopharm Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, February 8th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $18.00 target price on shares of Karyopharm Therapeutics in a report on Thursday, January 25th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Karyopharm Therapeutics presently has an average rating of “Buy” and an average target price of $18.56.
COPYRIGHT VIOLATION WARNING: “Karyopharm Therapeutics (KPTI) Scheduled to Post Earnings on Thursday” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/14/karyopharm-therapeutics-kpti-scheduled-to-post-earnings-on-thursday.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.